Ultragenyx

Company Profile

Ultragenyx had its IPO on 2014-01-31 under the ticker symbol RARE.

The company operates in the Healthcare sector and Biotechnology industry. Ultragenyx has a staff strength of 1,311 employees.

Stock update

Shares of Ultragenyx opened at $40.64 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $40.27 - $41.66, and closed at $41.41.

This is a +1.64% increase from the previous day's closing price.

A total volume of 798,247 shares were traded at the close of the day’s session.

In the last one week, shares of Ultragenyx have increased by +9.61%.

Ultragenyx's Key Ratios

Ultragenyx has a market cap of $2.91 billion, indicating a price to book ratio of 6.7978 and a price to sales ratio of 9.304.

In the last 12-months Ultragenyx’s revenue was $402.86 million with a gross profit of $-370780000 and an EBITDA of $-652508032. The EBITDA ratio measures Ultragenyx's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Ultragenyx’s operating margin was -167% while its return on assets stood at -31.95% with a return of equity of -178.6%.

In Q2, Ultragenyx’s quarterly earnings growth was a positive 0% while revenue growth was a positive 21.2%.

Ultragenyx’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

-0.24

Its diluted EPS in the last 12-months stands at $-10.25 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.24. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ultragenyx’s profitability.

Ultragenyx stock is trading at a EV to sales ratio of 6.7945 and a EV to EBITDA ratio of -3.744. Its price to sales ratio in the trailing 12-months stood at 9.304.

Ultragenyx stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$1.31 billion

Total Liabilities

$244.38 million

Operating Cash Flow

$0

Capital Expenditure

$16.44 million

Dividend Payout Ratio

0%

Ultragenyx ended 2024 with $1.31 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.31 billion while shareholder equity stood at $129.03 million.

Ultragenyx ended 2024 with $0 in deferred long-term liabilities, $244.38 million in other current liabilities, 71000.00 in common stock, $-3104822000.00 in retained earnings and $44.41 million in goodwill. Its cash balance stood at $102.06 million and cash and short-term investments were $551.98 million. The company’s total short-term debt was $10,884,000 while long-term debt stood at $0.

Ultragenyx’s total current assets stands at $702.14 million while long-term investments were $71.83 million and short-term investments were $449.92 million. Its net receivables were $70.52 million compared to accounts payable of $42.12 million and inventory worth $28.26 million.

In 2024, Ultragenyx's operating cash flow was $0 while its capital expenditure stood at $16.44 million.

Comparatively, Ultragenyx paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$41.41

52-Week High

$54.98

52-Week Low

$33.36

Analyst Target Price

$89.85

Ultragenyx stock is currently trading at $41.41 per share. It touched a 52-week high of $54.98 and a 52-week low of $54.98. Analysts tracking the stock have a 12-month average target price of $89.85.

Its 50-day moving average was $40.29 and 200-day moving average was $43.14 The short ratio stood at 6.58 indicating a short percent outstanding of 0%.

Around 466.5% of the company’s stock are held by insiders while 9857.9% are held by institutions.